Point72 Europe London LLP Buys New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Point72 Europe London LLP bought a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 43,568 shares of the biotechnology company's stock, valued at approximately $3,800,000. Point72 Europe London LLP owned 0.07% of Blueprint Medicines as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of BPMC. Point72 Hong Kong Ltd purchased a new position in Blueprint Medicines during the fourth quarter valued at $193,000. ProShare Advisors LLC grew its holdings in Blueprint Medicines by 33.9% during the fourth quarter. ProShare Advisors LLC now owns 20,915 shares of the biotechnology company's stock valued at $1,824,000 after purchasing an additional 5,290 shares during the period. Prosight Management LP boosted its position in shares of Blueprint Medicines by 42.3% in the fourth quarter. Prosight Management LP now owns 67,000 shares of the biotechnology company's stock worth $5,844,000 after purchasing an additional 19,900 shares during the period. Nuveen Asset Management LLC grew its position in shares of Blueprint Medicines by 49.2% during the fourth quarter. Nuveen Asset Management LLC now owns 419,190 shares of the biotechnology company's stock worth $36,562,000 after purchasing an additional 138,176 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Blueprint Medicines by 1.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,855 shares of the biotechnology company's stock valued at $3,736,000 after acquiring an additional 612 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wedbush restated an "outperform" rating and issued a $128.00 target price on shares of Blueprint Medicines in a report on Thursday, May 1st. Needham & Company LLC reduced their price target on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Wolfe Research assumed coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They issued an "outperform" rating for the company. JPMorgan Chase & Co. lifted their target price on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Finally, HC Wainwright restated a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.56.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $101.75, for a total transaction of $231,379.50. Following the transaction, the chief operating officer now directly owns 66,992 shares of the company's stock, valued at approximately $6,816,436. This trade represents a 3.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ariel Hurley sold 2,752 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $103.13, for a total value of $283,813.76. Following the completion of the transaction, the insider now directly owns 16,944 shares in the company, valued at approximately $1,747,434.72. The trade was a 13.97% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,503 shares of company stock worth $1,027,931. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Price Performance

BPMC stock opened at $97.51 on Thursday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90. The business has a 50 day simple moving average of $89.12 and a 200-day simple moving average of $94.07. The firm has a market capitalization of $6.30 billion, a PE ratio of -90.29 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same quarter last year, the business posted $1.40 EPS. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. Equities research analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.